Predicting cancer spread with a new imaging tool
Part of Cancer clinical trials.
This trial tests if a special imaging analysis can predict where your cancer might spread. It's for people with advanced lung, colorectal, or breast cancer who are starting or continuing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV non-small cell lung cancer (NSCLC), colorectal cancer, or breast cancer.
- You are able to care for yourself (ECOG score 0-2).
- You have had at least one type of cancer treatment like chemotherapy, targeted therapy, or immunotherapy.
- You have had scans (MRI, CT) before starting treatment and are willing to have regular follow-up scans.
- You have not already had cancer spread to certain organs (brain for lung cancer, liver for colorectal cancer, lung for breast cancer).
- You are expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
This study uses information from women with newly diagnosed breast cancer that has spread (metastatic) to create a tool that helps predict how the disease may progress. By looking at your medical records, they hope to improve care and help future patients.
Hear when a new Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.